DreaMed Launches its FDA-Cleared Diabetes Management Platform with a Leading U.S. Children's Hospital
Retrieved on:
Wednesday, October 20, 2021
Technology, Medical Devices, Hospitals, FDA, Genetics, Fitness & Nutrition, Clinical Trials, Biotechnology, Health, Data Management, Texas Children's Hospital, American Diabetes Association, Injection, Medtronic, Technology, Hospital, LTD, Diabetes, Glucose, Adviser, Yale New Haven Health System, FDA, CEO, More Than Just a Dream, Data analysis, Patient, University, Type 1 and type 2 sequence, The Company, Solution, Pediatrics, Pharmaceutical industry
DreaMed Diabetes AI LTD. ("DreaMed" or the "Company"), a developer of the Advisor Pro Al Clinical Decision Support platform for diabetes, announced today it deployed its DreaMeds Advisor Pro - a digital diabetes management platform in one of the top 10 metropolitan U.S. children's hospital1.
Key Points:
- DreaMed Diabetes AI LTD. ("DreaMed" or the "Company"), a developer of the Advisor Pro Al Clinical Decision Support platform for diabetes, announced today it deployed its DreaMeds Advisor Pro - a digital diabetes management platform in one of the top 10 metropolitan U.S. children's hospital1.
- Advisor Pro by DreaMed is an Al Clinical Decision Support System for diabetes, providing remote insulin management with data analysis and therapy management tools.
- The solution was deployed at the hospital together with existing diabetes management protocols so patients can receive a personalized, precise, and effective diabetes treatment.
- Since then, DreaMed Diabetes has been vigorously working on the DreaMed Advisor portfolio, decision support tools in diabetes management.